Teriparatide oral - Entera Bio

Drug Profile

Teriparatide oral - Entera Bio

Alternative Names: EB 612; EB 613; EP-101 - Entera Bio; Parathyroid hormone oral - Entera Bio; Parathyroid hormone-1-34 - Entera Bio; PTH oral - Entera Bio; PTH-1-34 - Entera Bio

Latest Information Update: 24 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Entera Bio
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoparathyroidism
  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypoparathyroidism
  • Phase I Osteoporosis

Most Recent Events

  • 24 Jul 2018 Entera Bio plans a clinical trial for Hypoparathyroidism in USA and United Kingdom (Entera Bio website, July 2018)
  • 24 Jul 2018 Entera Bio plans a dose ranging phase IIa trial for Osteoporosis in USA (Entera Bio website, July 2018)
  • 04 May 2018 Entera Bio initiates a phase II trial for Hypoparathyroidism in Israel , (NCT03516773)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top